Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma.
Heim C, Moser LM, Kreyenberg H, Bonig HB, Tonn T, Wels WS, Gradhand E, Ullrich E, Meister MT, Koerkamp MG, Holstege FCP, Drost J, Klusmann JH, Bader P, Merker M, Rettinger E. Heim C, et al. Among authors: klusmann jh. Front Immunol. 2023 Aug 18;14:1228894. doi: 10.3389/fimmu.2023.1228894. eCollection 2023. Front Immunol. 2023. PMID: 37662907 Free PMC article.
Bortezomib promotes the TRAIL-mediated killing of resistant rhabdomyosarcoma by ErbB2/Her2-targeted CAR-NK-92 cells via DR5 upregulation.
Heim C, Hartig L, Weinelt N, Moser LM, Salzmann-Manrique E, Merker M, Wels WS, Tonn T, Bader P, Klusmann JH, van Wijk SJL, Rettinger E. Heim C, et al. Among authors: klusmann jh. Mol Ther Oncol. 2024 Apr 11;32(2):200802. doi: 10.1016/j.omton.2024.200802. eCollection 2024 Jun 20. Mol Ther Oncol. 2024. PMID: 38706988 Free PMC article.
PDP1 is a key metabolic gatekeeper and modulator of drug resistance in FLT3-ITD-positive acute myeloid leukemia.
Alshamleh I, Kurrle N, Makowka P, Bhayadia R, Kumar R, Süsser S, Seibert M, Ludig D, Wolf S, Koschade SE, Stoschek K, Kreitz J, Fuhrmann DC, Toenges R, Notaro M, Comoglio F, Schuringa JJ, Berg T, Brüne B, Krause DS, Klusmann JH, Oellerich T, Schnütgen F, Schwalbe H, Serve H. Alshamleh I, et al. Among authors: klusmann jh. Leukemia. 2023 Dec;37(12):2367-2382. doi: 10.1038/s41375-023-02041-5. Epub 2023 Nov 7. Leukemia. 2023. PMID: 37935978 Free PMC article.
Myeloid leukemia vulnerabilities embedded in long noncoding RNA locus MYNRL15.
Ng M, Verboon L, Issa H, Bhayadia R, Vermunt MW, Winkler R, Schüler L, Alejo O, Schuschel K, Regenyi E, Borchert D, Heuser M, Reinhardt D, Yaspo ML, Heckl D, Klusmann JH. Ng M, et al. Among authors: klusmann jh. iScience. 2023 Sep 7;26(10):107844. doi: 10.1016/j.isci.2023.107844. eCollection 2023 Oct 20. iScience. 2023. PMID: 37766974 Free PMC article.
The lncRNA MIR99AHG directs alternative splicing of SMARCA1 by PTBP1 to enable invadopodia formation in colorectal cancer cells.
Li D, Wang X, Miao H, Liu H, Pang M, Guo H, Ge M, Glass SE, Emmrich S, Ji S, Zhou Y, Ye X, Mao H, Wang J, Liu Q, Kim T, Klusmann JH, Li C, Liu Z, Jin H, Nie Y, Wu K, Fan D, Song X, Wang X, Li L, Lu Y, Zhao X. Li D, et al. Among authors: klusmann jh. Sci Signal. 2023 Sep 19;16(803):eadh4210. doi: 10.1126/scisignal.adh4210. Epub 2023 Sep 19. Sci Signal. 2023. PMID: 37725664
Double trouble: IRAK1/4 inhibitors in AML/MDS.
Uckelmann HJ, Klusmann JH. Uckelmann HJ, et al. Among authors: klusmann jh. Blood. 2023 Sep 14;142(11):945-946. doi: 10.1182/blood.2023020812. Blood. 2023. PMID: 37707874 No abstract available.
Down syndrome and leukemia: from basic mechanisms to clinical advances.
Baruchel A, Bourquin JP, Crispino J, Cuartero S, Hasle H, Hitzler J, Klusmann JH, Izraeli S, Lane AA, Malinge S, Rabin KR, Roberts I, Ryeom S, Tasian SK, Wagenblast E. Baruchel A, et al. Among authors: klusmann jh. Haematologica. 2023 Oct 1;108(10):2570-2581. doi: 10.3324/haematol.2023.283225. Haematologica. 2023. PMID: 37439336 Free PMC article. Review.
90 results